More on AMRN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.99 |
|
|||
| Open | $11.99 | ||||
| 52 Wk High | $3.65 | ||||
| 52 Wk Low | $1.24 | ||||
| Day High | $12.10 | ||||
| Day Low | $11.99 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,570 | ||||
- Amarin presents new REDUCE-IT data at ESC Congress 2026
- Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
- Amarin presents REDUCE-IT legacy analysis at ESC Congress 2026
- New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Pat
- Amarin to present REDUCE-IT analyses at ESC Congress 2026
- New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- Form 4 AMARIN CORP PLC\UK For: Aug 01 Filed by: Fishman Peter L.
- Amarin Corp. (AMRN) Reports In-Line Q2 EPS
- Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Entities mentioned with AMRN
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- AdCom | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Options | View Related Stories »
- Show More...
